Background. Tunnelled femoral catheters with their tip in the lower inferior vena cava (IVC) are proposed only in few cases, but they often provide less than optimal blood flows and frequently have complications. The aim of this prospective observational study is to evaluate the use of 70-cm-long tunnelled cuffed femoral twin Tesio catheters with their tip in the upper IVC for haemodialysis. Results. Technical success of placement was 100%. The 6-and 12-month assisted primary patency rate were respectively 67 ± 13% and 54 ± 17%. The mean session Kt/V was 1.45 ± 0.19, and the blood flow was 270 ± 17 ml/ min. Six fCVCs have been removed: three for infection, one for accidental damaging and two for the making of a different vascular access. The main complications were 2 catheter tip thrombi, 3 tunnel infections and 11 fCVCrelated bacteraemia (1.77 episodes per 1000 CVC-days). Conclusion. The placement of twin fCVCs with their tip in the high IVC can provide an adequate dialysis and can be considered for patients with no remaining thoracic accesses.
Introduction
The progressive ageing of the patients on haemodialysis has raised again the question of haemodialysis vascular access, particularly in very old patients and in patients with a severe comorbidity burden [1] [2] [3] . Tunnelled central venous catheters (CVC) are frequently used as either a midterm or a long-term haemodialysis access, but they are not a first choice access as a 'permanent' vascular access [4] . Tunnelled CVC may be used as a 'bridge' while creating an arteriovenous fistula or graft [5, 6] . They may also be proposed to very old patients with heart failure and a poor venous legacy because the creation of a haemodialysis graft may worsen the grade of the cardiopathy [7, 8] .
The preferred CVC site is the internal jugular vein, but in case of previous catetherizations with residual stenosis or thrombosis, it may be difficult to cannulate [9, 10] . Moreover, some patients may be exposed to an increased risk during CVC positioning; these patients may benefit from a less invasive approach, and the femoral route has a lower complication rate [11] .
The transfemoral route to inferior vena cava (IVC) has been successfully used either with twin single-lumen CVC [12, 13] or with a single double-lumen CVC [14, 15] . In most cases, the tip of the CVC was located in the lower third of the IVC, and only rarely it reached the upper third of the IVC or the IVC-right atrium junction [13, 15] . In one study, when the CVC had to be changed for malfunction, a longer CVC was placed and granted an adequate dialysis blood flow [15] . The complication rate of femoral CVC was low, and the most common complications were the infective ones [16, 17] .
There is no agreement in literature on which tunnelled femoral CVC for haemodialysis is the most efficient, but it appears that CVCs with their tips in the upper IVC may have a better function without greater complications. In this study, we placed in each patient two single-lumen tunnelled cuffed 70-cm-long Tesio catheters with their tips in the upper IVC through a transfemoral route (fCVC); the purpose of the study was to evaluate the use and complication rate of these catheters.
Subjects and methods
In this prospective observational study (May 2007-May 2009), 25 twin tunnelled cuffed femoral Tesio CVCs have been placed in 25 patients. All the patients have been informed on the procedural risks, benefits and alternatives and have given their written informed consent to have the fCVC placed.
A fCVC has been placed as a bridge to a permanent dialysis access in two late referred patients and in three patients with an acute failure of their vascular access. When an arteriovenous fistula or graft was not feasible due to lack of superficial veins and in presence of a severe dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) <30%, a tunnelled CVC was proposed. The option of a femoral tunnelled CVC was considered if the patient had exhausted thoracic vein accesses (eight patients) or if the patient was considered to be at high procedural risk of placing a jugular CVC (12 patients). This latter group included patients with severe heart failure (New York Heart Association class IV), a Charlson comorbidity index (CCI) >6 and an age >75.
The CCI, adjusted for end-stage renal disease, is a simple and synthetic score used to evaluate the overall comorbidity burden. It has a good correlation to the patient's prognosis: a CCI >6 is related to a patient survival of <12 months [18] . This index is calculated adding the score given to each disease state that is present at the moment of the calculation; in its original version, 19 different pathologies were included, but we used the score modified by Hemmelgarn et al. for use in end-stage renal disease, which includes 14 pathologies [18] . It is actually used to measure the patient comorbidities and estimating survival for both clinical and research purposes.
In this study, we used single-lumen carbothane Tesio Catheters (Gemini, BellCo, Mirandola (MO), Italy) which were 70 cm long with end and side ports, had a diameter of 10 Fr (= 3.3 mm) and a Dacron cuff at 45 cm from the tip. Carbothane is an aliphatic polyurethane group, based on polycarbonate. It has a low thrombogenicity and the same softness as silicone elastomers. Before the procedure, all patients were given prophylactic antibiotics (Ceftriaxone 2 grams). All the procedures were performed in an angiography suite with an intermittent fluoroscopic guidance and continuous electrocardiogram monitoring, by two interventional nephrologists who are trained to place jugular, subclavian and femoral catheters.
The right common femoral vein has been chosen as a first choice because it is usually shorter and less tortuous than the left common femoral vein, which has been used if there was any cannulation difficulty or vein thrombosis of the right femoral vein.
After local anaesthesia (Lidocain 2%), the femoral vein was punctured using an 18-gauge × 7 cm needle. A 0.035" × 150 cm guidewire with a J tip was introduced in the vein and the needle removed. The second puncture was performed 3-6 mm lower with the same technique to place a second guidewire. The correct positioning of the guidewires was controlled under fluoroscopy. The skin was cut between the two guidewires to permit a better tunnelization later during the procedure.
A 9 Fr (= 3 mm) vessel dilator was used over the guidewire, and then an 11 Fr (= 3.6 mm) vessel dilator with peel away sheath was placed. The first catheter was introduced in the peel away over the guidewire under continuous fluoroscopic guidance, and then, the guidewire was removed. The second catheter was placed using the same technique. All the tips reached the upper third of the IVC or the junction of the IVC and right atrium (see Figure 1) .
In 21 pts, a straight 10-cm-long tunnel was created in the thigh using the tunnelling instrument included in the catheter kit. In 4 pts, the tunnel was curved backwards in the abdomen, with the exit site 4-5 cm above the inguinal ligament.
All the fCVCs underwent an infection surveillance program which included a protocol of sterile CVC connection and disconnection with two operators during the haemodialysis session. This protocol involved one operator who wore single-use gown, mask and cap and sterile gloves during the connection and disconnection procedures, with the help of the other 'non-sterile' operator.
Each CVC was locked after each dialysis session with 2.5 ml of unfractionated Heparin 5000 IU/ml and once every month with a urokinaseheparin lock solution (urokinase 5000 U/ml heparin 2500 IU/ml).
The haemodialysis adequacy was measured using the single-pool urea Kt/V with the second generation Daugirdas formula [19] . The data of effective blood flow (Qb), aspiration pressure (Pa) and restitution pressure (Pv) were obtained by the mean of three consecutive dialysis sessions performed within the first month after the fCVC placement.
Malfunction was defined as the inability of maintaining an effective blood flow of at least 200 ml/min. Any obvious kinking or malpositioning was corrected, and if the flow was not restored, an intracatheter fibrinolytic therapy was performed with urokinase 5000 U/ml (12.500 U per CVC). If the thrombolytic therapy was not effective, the fCVC was replaced with a new one. The placement of fCVC was not considered an indication to start or change the antiplatelet or anticoagulant therapy.
Catheter-related bacteraemia was defined as body temperature >38°C during or soon after the dialysis session without any other clinical symptom and was confirmed by double haemocultures (peripheral vein and catheter). The empiric antibiotic treatment was systemic vancomycin 1 gram and gentamycin 1 mg/kg, followed by vancomycin 2 grams/week and gentamycin 1 mg/kg after each session [20] . A local antibiotic lock therapy was performed with a solution made of gentamycin 1 mg/ml and unfractionated heparin 2500 IU/ml. The antibiotic therapy was adjusted according to the antibiogram and performed for 3 weeks [20] . The fCVC was removed in case of bacteraemia that did not respond to antibiotics or in presence of a tunnel infection [21] .
Since a prophylactic thrombolytic therapy was performed, we defined an assisted primary patency rate from the time of CVC placement to patient death with functioning catheter, conclusion of the study with functioning catheter, device failure (exchange or removal) or any intervention to restore patency, including urokinase therapy for malfunction, but not protocol urokinase prophylaxis [22] .
Secondary patency rate has been calculated up to CVC exchange or removal, for either infection, malfunction or other mechanical complications [22] .
Patient survival has been calculated from CVC placement up to patient death with functioning catheter or if the patient died within 3 months of CVC removal. Patient survival and patency rates have been calculated using an actuarial event-free survival (Kaplan Meyer). All the results are expressed as mean ± standard deviation (SD) and min-max range. Total follow-up was 6191 CVC-days.
Results
The technical success of placement and initial function was 100%. Among the early complications, we did not observe any severe complication, including acute anaemia needing transfusions, retroperitoneal bleeding, arterial or venous laceration or cardiac perforation, but there were eight haematomas (32 %) and two soft tissue swellings around the tunnel (8 %). The 6-and 12-month assisted primary patency rates were, respectively, 66.6% ± 12.6% and 54.2% ± 16.6%. Secondary patency rate was at 6 months 85% ± 8.8% and at 12 months 65% ± 16.8%; none of the fCVCs was exchanged or removed for malfunction. Overall, six fCVCs were removed for the following reasons: two patients had a new vascular access, two tunnel infections, one accidental damaging of the fCVC and one patient had a severe limb swelling and tunnel infection without echographic signs of vein thrombosis. In these patients, a not-tunnelled controlateral femoral catheter has been used. The main patients characteristic are shown in Table 1 . The age at the time of fCVC placement was 77.7 ± 10.8 years (range 49-92 years), which included young patients with vascular access problems and old patients with several comorbidities; these older patients were the ones in which the fCVC was used as first vascular access (12/25). Most of the patients (22/25) were on antiplatelet or anticoagulant therapy before the fCVC placement because of 'non-vascular-access' reasons. Three patients were not on either antiplatelet or anticoagulant therapy because they were malnourished (n = 2) or had a severe hepatopathy (n = 1).
The overall patient survival was 74.7% at 6 months and 63.4% at 12 months, which includes nine deaths with functioning catheter and one after CVC removal (accidental damage): three vascular cachexia (one after suspension of dialysis treatment), two neoplastic cachexia, three sudden deaths, one heart failure and one sepsis from limb gangrene (homolateral, but apparently not correlated to the presence of the fCVC).
The mean session Kt/V was 1.45 ± 0.19 (range 1.04-1.85), and the blood flow was 270 ± 17 ml/min (Table 2) . Even if some fCVCs had a high arterial and venous pressures (>200 mmHg), no clotting of the circuit has been observed.
Among the main complications, we observed two catheter tip thrombi in two different patients, diagnosed by computed tomography (CT): the first was 50 mm long and 6 mm of diameter, while the second was 16 mm long and had a diameter of 4 mm. There was also one deep vein thrombosis with leg swelling and without pulmonary embolism; these patients started an anticoagulant therapy with warfarin keeping a prothrombin time-international normalized ratio of 2.0-2.5. Two of them concluded the study with a functioning CVC, while the other died from vascular cachexia.
During the follow-up, we observed 11 fCVC-related bacteraemia, with a rate of 1.77 episodes per 1000 CVCdays. The haemocultures were positive for Staphylococcus aureus (n = 4), coagulase negative Staphylococci (n = 1), polymicrobial (n = 3) and Enterobacteriaceae (n = 1), and two had a negative culture. There was an associated tunnel infection in 3 pts, in which the fCVCs had to be removed. Other infective complications included 11 local infections in the site of the double vein cannulation in 8 pts, treated with local antibiotic therapy with good response. These infections were early and superficial; they involved the skin incision above the site of the venipuncture and did not go to the CVC tunnel.
Discussion
The use of twin tunnelled cuffed femoral CVC with the tip in the upper IVC for haemodialysis has been investigated in this study. The use of two 10 Fr (= 3.3 mm) single-lumen CVC in femoral vein has not led to serious complications during the placement manoeuvres and during the follow-up even considering the diameter of the femoral vein (7-10 mm) . This is probably due to the good biocompatibility of the catheter material (carbothane). The IVC diameter below the diaphragm is about 10 mm/m 2 of body surface (see Figure 2) ; the vein blood flow at this level is very high because it collects all the blood from the lower half of the body [22] . In patients with high central venous pressure due to a dilated cardiopathy, the IVC has even a higher diameter [24] .
There are some reports in literature of tunnelled cuffed femoral CVC, either single lumen or double lumen, that usually have the CVC tip in the inferior segment of the IVC [14] [15] [16] 22, 26] . In our experience, fCVCs had a mean Qb of 270 ml/min and a Kt/V of 1.45; therefore, these catheters could be able to give an adequate blood flow. The primary patency observed in our series was 66.6% ± 12.6% at 6 months and 54.2% ± 16.6% at 12 months; this result does not seem to be inferior to those reported in literature with other tunnelled cuffed femoral CVCs, although a direct comparison between different case series Body mass index is the weight in kilograms divided by the square of the height in metres. cannot be easily done. Moreover, the data that can be derived from different studies are frequently not uniform, and the definition of CVC patency that has been used may be a little different from author to author. Zaleski et al. showed a 6-month primary patency (as time from placement to substitution or removal) of 55% using 40-60 cm long double-lumen femoral CVC [15] . Maya et al. had a 6-month primary patency (from insertion to first exchange) of <20% using 36-42-cm-long double-lumen femoral CVC with their tip in the lower IVC; they had a mainly black population, but with a relatively young age [16] . Chow et al. had mean femoral CVC survival of 166 days (from placement to malfunction, defined as effective blood flow of <180 ml/min), but only 7/14 (50%) remained in site after 3 months [25] . None of these authors has reported a program of periodic thrombolytic 'prophylaxis'; in our center, all the CVCs are locked with urokinase every month, and this could be a reason for the patency rate observed in our series [27] . To be pointed out, none of the CVCs we placed had to be removed for malfunction, which is in contrast with the literature on tunnelled femoral CVCs [15, 16] that shows a high number of CVC substitution for malfunction. A major problem in femoral CVC is the high infection rate, leading often to CVC malfunction or removal; the incidence of CVC-related bacteraemia in our series was 1.77 episodes per 1000 CVC-days. This result is in keeping with the literature on tunnelled femoral CVC. Zaleski et al. [15] showed a total (needing removal and not removed CVC) infection rate of 5.2/1000 CVC-days, and Chow et al. had an infection rate of 3.8/1000 CVC-days [25] . In a relatively large series of translumbar CVC, the infection rate was 2.8/1000 CVC-days [28] . It is hard to compare the incidence of infection between different dialysis units [29] ; in our center, we observe a strict infection surveillance programme and manage the connection and disconnection with two operators. A Canadian prospective surveillance programme showed a cuffed CVC-related blood stream infection rate of 3.1/1000 dialysis procedures, which is similar to our incidence with cuffed femoral CVC alone [29] .
Nevertheless, we observed three cases of thrombosis: two catheter tip thrombi and a deep venous thrombosis. These observations raise the question about the need of an anticoagulant or antiplatelet therapy when the catheter is placed. Considering the magnitude of the problem of thrombosis in patients with CVC, prophylaxis is important and should begin at the time of CVC use [27] . The use of warfarin as a prophylactic agent in thoracic vein CVC did not show any significant benefit, but probably controlled studies are needed [30] . In our opinion, the use of warfarin is not justified in femoral CVC in absence of thrombosis; we believe that a double antiplatelet therapy may be effective in preventing the formation of thrombi.
Long-term complications of CVC include vein thrombosis and stenosis. In our limited report, we did not observe any vein stenosis, but the mean patient follow-up is only 248 days. However, this problem should not be underestimated, especially in young patients, in which the fCVC has been used as a mid-term access; they should undergo a strict surveillance. For the same reason, patients who could be eligible for kidney transplantation should not be proposed for this access even for a relatively short period of time.
Most patients who required a femoral CVC had a very limited mobility, so a CVC placed in their femoral vein did not limit their routine activity. At first, we tunnelled the CVC inferiorly in the thigh, but later, we proposed a different tunnel upward toward the abdomen to reduce the infection rate of the exit site. The comparison between these two techniques cannot be done with the actual data because most of the patients (21/25) had a downward tunnel.
In summary, the placement and use for chronic haemodialysis of twin 70-cm-long tunnelled cuffed femoral Tesio catheters could be considered as an option if a femoral CVC is needed. The dialysis dose can be adequate and the incidence of thrombosis, infection and malfunction is relatively low. The relatively low complication rate of the use of fCVCs could be probably due to the preventive measures adopted in our center: periodic thrombolysis, infection surveillance and prophylaxis, with a two-operator protocol of sterile connection and disconnection procedures. The long-term complications of this technique are not known, therefore, it should be used only as a mid-term dialysis access and not in patients who are eligible for kidney transplantation.
